NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 127 filers reported holding NEKTAR THERAPEUTICS in Q4 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $4,109,153 | +95085.4% | 3,313,833 | -28.3% | 0.01% | 0.0% |
| Q1 2024 | $4,317 | +43.5% | 4,620,681 | -13.2% | 0.01% | +40.0% |
| Q4 2023 | $3,009 | +44.0% | 5,325,475 | +51.9% | 0.01% | +25.0% |
| Q3 2023 | $2,089 | -11.3% | 3,506,681 | -14.3% | 0.00% | +33.3% |
| Q2 2023 | $2,354 | +11.5% | 4,091,681 | +36.2% | 0.00% | 0.0% |
| Q1 2023 | $2,111 | +696.6% | 3,003,696 | +2464.8% | 0.00% | – |
| Q4 2022 | $265 | -100.0% | 117,111 | -64.2% | 0.00% | -100.0% |
| Q2 2019 | $11,636,000 | +68.6% | 327,048 | +59.2% | 0.01% | +66.7% |
| Q1 2019 | $6,903,000 | -47.8% | 205,448 | -48.9% | 0.01% | -57.1% |
| Q4 2018 | $13,212,000 | +214.8% | 401,948 | +483.8% | 0.01% | +250.0% |
| Q3 2018 | $4,197,000 | +197.9% | 68,848 | +138.7% | 0.00% | +300.0% |
| Q2 2018 | $1,409,000 | -74.3% | 28,848 | -68.6% | 0.00% | -83.3% |
| Q4 2017 | $5,485,000 | -12.2% | 91,848 | -83.8% | 0.01% | -53.8% |
| Q1 2015 | $6,249,000 | -6.7% | 568,048 | +31.4% | 0.01% | -18.8% |
| Q4 2014 | $6,698,000 | – | 432,148 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
| MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
| Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
| Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
| Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
| Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
| CM Management, LLC | 35,000 | $595,000 | 0.55% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
| RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
| Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |